Kathryn Romano - 27 Feb 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Accounting Officer
Signature
/s/ Kathryn Romano
Issuer symbol
KRYS
Transactions as of
27 Feb 2026
Net transactions value
-$1,165,991
Form type
4
Filing time
03 Mar 2026, 18:33:55 UTC
Previous filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ROMANO KATHRYN Chief Accounting Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH /s/ Kathryn Romano 03 Mar 2026 0001801385

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $0 +7,500 +40% $0.000000 26,068 27 Feb 2026 Direct F1
transaction KRYS Common Stock Tax liability $899,138 -3,262 -13% $275.64 22,806 27 Feb 2026 Direct F2, F3
transaction KRYS Common Stock Options Exercise $0 +550 +2.4% $0.000000 23,356 27 Feb 2026 Direct F4
transaction KRYS Common Stock Tax liability $66,154 -240 -1% $275.64 23,116 27 Feb 2026 Direct F3, F5
transaction KRYS Common Stock Sale $200,700 -750 -3.2% $267.60 22,366 02 Mar 2026 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Performance Stock Units Options Exercise $0 -7,500 -100% $0.000000 0 27 Feb 2026 Common Stock 7,500 Direct F1
transaction KRYS Restricted Stock Units Options Exercise $0 -550 -25% $0.000000 1,650 27 Feb 2026 Common Stock 550 Direct F4
transaction KRYS Stock Option (Right to Buy) Award $0 +13,575 $0.000000 13,575 27 Feb 2026 Common Stock 13,575 $275.64 Direct F7
transaction KRYS Restricted Stock Units Award $0 +5,442 $0.000000 5,442 27 Feb 2026 Common Stock 5,442 Direct F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.
F2 Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.
F3 The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.
F4 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.
F5 Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.
F6 The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.
F7 The stock options vest in four equal annual installments beginning on February 27, 2027.
F8 Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
F9 The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
F10 The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.